Quick Answer
Scinai Immunotherapeutics Ltd. reported Stockholders Equity of $9.98 million for fiscal year 2024.
Scinai Immunotherapeutics Ltd. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2024 | $9.98M | +318.4% |
| 2023 | -$4.57M | -159.6% |
| 2022 | -$1.76M | -279.2% |
| 2021 | $982.0K | +106.5% |
| 2020 | -$15.04M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| March 31, 2023 | -$4.81M | -458.0% | -173.3% |
| December 31, 2022 | -$1.76M | -279.2% | -104.2% |
| March 31, 2022 | -$862.0K | — | -187.8% |
| December 31, 2021 | $982.0K | — | — |
- Scinai Immunotherapeutics Ltd. showed an increase of +318.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2020–2024 period, Scinai Immunotherapeutics Ltd.’s stockholders equity has grown by 166.3% (from -$15.04 million to $9.98 million).
- The most recent figure is from Scinai Immunotherapeutics Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on May 7, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: